Corrigendum notice
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation Appendix 22: Table 96 is replaced with the following text: Table 96 has been removed as it includes incorrect hazard ratios caused by a reversal of the hazard ratio calculations. However, this does not impact on any of the clinical or economic results reported.
Chapter 3, under the heading 'Survival risk at year 1 and year 2 post randomisation': The following text is removed:
Analyses for 1-year survival show no evidence to suggest any difference in survival between the thirdgeneration chemotherapy treatments except for PEM + PLAT compared with GEM + PLAT that demonstrated significant evidence of 1-year survival advantage for PEM over GEM.
